HCmed Innovations (心誠鎂) and its partner, United Therapeutics (UT), have successfully reached their first development milestone for a Pulmonary Arterial Hypertension (PAH) therapy. In November, HCmed Innovations recognized NT$70.82 million in milestone revenue, signifying stable progress in their collaboration.

This project combines HCmed Innovations’s expertise in innovative drug delivery technology (high-end nebulizers) with UT’s deep experience in rare lung diseases. HCmed Innovations Chairman Cheng Chieh-sheng stated that this achievement highlights the company’s technical prowess in the high-end CDMO market for drug-device combination products. Once the product is commercialized, it is expected to provide a consistent and significant revenue stream.

Resource: 心誠鎂攜手美國大藥廠，合作開發成功獲首階里程碑金7千萬元